Linker-MM4 data raise more questions about sequencing of therapies for multiple myeloma.
ApexOnco Front Page
Recent articles
Pfizer reveals the discontinuation of PF-08046044.
The company will be the first to take a FcRH5-targeting project into phase 3.
Like Orserdu, giredestrant works in all-comers in an ESR1m-enriched trial.
Big pharma interest remains, but the mood is fast turning gloomy.
The Rosetta Breast-01 phase 3 trial will only evaluate patients with low PD-L1 expression.
The recently unveiled conjugate DS3610a is to start phase 1.
A phase 3 trial of the Scorpion-originated tersolisib will be in first-line breast cancer.
